Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Expression levels of atherosclerosis-associated miR-143 and miR-145 in the plasma of patients with hyperhomocysteinaemia

Contributed equally
BMC Cardiovascular DisordersBMC series – open, inclusive and trusted201717:163

https://doi.org/10.1186/s12872-017-0596-0

Received: 8 February 2017

Accepted: 9 June 2017

Published: 20 June 2017

Abstract

Background

An elevated level of homocysteine (Hcy) in the blood is designated hyperhomocysteinaemia (Hhcy) and is regarded as a strong risk factor for the development of atherosclerosis (ATH), although the association remains controversial. Considered to be essential gene expression regulators, micro-RNAs (miRNAs) modulate cardiovascular disease development and thus can be regarded as potential biomarkers and therapeutic targets in atherosclerosis. The aim of the current study is to investigate the expression levels of atherosclerosis-associated miR-143 and miR-145 in Hhcy patients and predict the progress of atherosclerosis in Hhcy patients.

Methods

A total of 100 participants were enrolled and included normal control subjects (NC = 20), hyperhomocysteinaemia alone subjects (Hhcy = 25), hyperhomocysteinaemia and carotid artery atherosclerosis combined subjects (Hhcy + ATH = 30) and patients with standalone carotid artery atherosclerosis (ATH = 25). Plasma Hcy, supplementary biochemical parameters and carotid artery ultrasonography (USG) were measured in all participants. MicroRNA expression levels in the peripheral blood were calculated by real-time reverse transcription-polymerase chain reaction (qRT-PCR). The correlations of miR-143 and miR-145 with Hcy, blood lipid parameters and carotid artery atherosclerotic plaques were evaluated using Pearson’s correlation coefficients. Receiver operating characteristic (ROC) curve analyses were performed to evaluate the capacities of miR-143 and miR-145 for the detection of Hhcy and atherosclerosis patients.

Results

MiR-143 and miR-145 exhibited trends towards significance with stepwise decreases from the NC to Hhcy groups and then to the Hhcy + ATH and ATH groups. Similar results were observed in the carotid artery plaque group (Hhcy + ATH and ATH grups) compared with the no-plaque group (NC and Hhcy groups). The miR-143 expression level exhibited significant negative correlations with Hcy, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c). The miR-145 expression level exhibited significant negative correlations with Hcy, TC, triglyceride (TG) and LDL-c. MiR-143 and miR-145 exhibited the greatest area under the curves (AUCs) (0.775 and 0.681, respectively) for the detection of every Hhcy patient, including those in the Hhcy and Hhcy + ATH groups, from among all subjects.

Conclusion

The results indicated that the levels of atherosclerosis-associated circulating miR-143 and miR-145 are linked to Hhcy. MiR-143 may be used as a potential non-invasive biomarkers of Hhcy and thus may be helpful in predicting the progress of atherosclerosis in Hhcy patients.

Keywords

miR-143 miR-145 Hyperhomocysteinaemia Atherosclerosis Correlation

Background

Homocysteine (Hcy) is an intermediate substance that is formed in the metabolic pathway of cysteine and methionine. Hyperhomocysteinaemia (Hhcy) is regarded as an emerging risk factor for the development of atherosclerosis and a variety of other cardiovascular diseases, such as coronary artery disease (CAD), hypertension, stroke, etc. [13]. Recent studies have demonstrated that homocysteine initiates an inflammatory response in vascular smooth muscle cells (VSMCs) and triggers the proliferation and migration of VSMCs [4, 5]. Moreover, it is well established that VSMC proliferation and migration play fundamental roles in the development of atherosclerosis [6, 7]. We hypothesize that Hhcy may induce the process of atherosclerosis. Although several studies have implicated Hhcy in atherosclerosis, the exact mechanism is not entirely understood.

MicroRNAs (miRNAs) are single-stranded noncoding RNA molecules of 22 nucleotides. miRNAs inhibit mRNA translation by interacting with the 3′ untranslated region (UTR) [810]. To determine the ability of atherosclerosis-associated microRNAs to predict the presence of atherosclerosis in Hhcy patients, miRNA databases (i.e., the TargetScan database, http://www.targetscan.org/ and miRBase, http: //http://www.mirbase.org/) [11] and other relevant literature were searched. MiR-143 and miR-145 were confirmed to be critical factors in the development of atherosclerosis [12]. Circulating miR-143 is critical for the regulation of VSMC phenotypes because it promotes differentiation and prevents the proliferation of VSMCs [13, 14]. Because miR-145 is the most abundant miRNA in the vascular wall, it plays a crucial role in differentiation of VSMCs and inhibits their proliferation [15, 16].

There is accumulating evidence demonstrating that miRNAs are a key factor in the development of atherosclerosis [9, 13, 17, 18] and other cardiovascular diseases. Down-regulation of miR-143/−145 has been predominantly expressed in VSMCs and play a role in several cardiovascular diseases, such as hypertension and coronary artery disease (CAD). Recent clinical fndings have demonstrated that the expression levels of miR-143/−145 were decreased in essential hypertension patients compared with healthy subjects [19, 20]. MiR-145 contributes to the pathogenesis of hypertension, as it mediates stretch-induced differentiation of VSMCs [21, 22]. These findings highlight the importance of miR-143/−145 as potential biomarkers for cardiovascular diseases. Vascular smooth muscle cells play an important role in plaque stabilization, particularly in the progression of atherosclerosis [23]. Gain and loss of function of VSMC-enriched miR-143/−145 in vivo results in reduced proliferation, which consequently limits neointima formation in vascular injury models. This leads to the assumption that the miR-143/−145 are inevitable for the pro-proliferative response of VSMCs to injury [24, 25]. This suggests that downregulation of miR-143/−145 may contribute to atherogenesis. MiR-143/−145 are relatively specific for VSMCs and thus are closely correlated with cardiovascular diseases such as atherosclerosis, hypertension and CAD.

However, the exact correlates of the expressions of atherosclerosis-associated microRNAs in Hhcy patients have yet to be fully elucidated. To determine whether these two miRNAs are related to hyperhomocysteinaemia and thus to the development of atherosclerosis, a study was conducted that involved a comparison of their expression levels in the plasma of hyperhomocysteinaemia alone patients and patients with both hyperhomocysteinaemia and carotid atherosclerosis and to further examine whether miRs-143/145 are related directly to hyperhomocysteinaemia and the development of carotid atherosclerotic plaques in humans, the associations with hyperhomocysteinaemia and atherosclerosis were re-analysed from a different perspective.

Methods

Research subjects

For this study, hyperhomocysteinaemia was defined as a plasma Hcy level above 15 μm/L [26]. Carotid artery atherosclerosis was determined by carotid artery ultrasonography (USG), which was used to determine the presence of plaque formation, which in turn was used to categorize the subjects into plaque and no-plaque groups. Approximately 310 newly diagnosed Hhcy patients were screened in the Department of Cardiovascular Diseases of the First Affiliated Hospital of Shihezi University Medical College from January 2014 to December 2015. Patients with histories of hypertension, ischaemic heart disease, diabetes mellitus, chronic liver diseases, chronic renal diseases and excessive drinking plus smoking were excluded. Ultimately, only 167 Hhcy patients were included. Of these, 30 Hhcy + ATH patients and 25 Hcy standalone patients were selected. The two groups were matched for age, sex, body mass index (BMI). Additionally, 25 ATH and 20 NC subjects were selected and were matched to the Hhcy + ATH group for age, sex and BMI. These subjects were extracted from 800 individuals who were already receiving health check-ups at the physical examination centre of the First Affiliated Hospital of Shihezi University Medical College during the same period.

Carotid artery ultrasonography to determine plaque formation

All patients underwent carotid artery ultrasonography (USG) to determine plaque formation. The patients were asked to lie down one by one in a semi-dark room in the supine position with their neck slightly extended and rotated away from the imaging transducer. Both the right and left carotid arteries and the bifurcation were visualized by an experienced radiologist via an ultrasonography device (Hitachi) using a 9-MHz linear probe. According to the study criteria, the absence of atherosclerotic plaque was considered “normal”, and positive results were indicative of atherosclerotic plaque [27].

Biochemical assays

Whole blood samples were collected in Ethylene Diamine Tetraacetic Acid (EDTA) tubes from each subject in the morning after an 8-h fast. Plasma Hcy, TG, TC, high-density lipoprotein cholesterol (HDL-c), LDL-c, apolipoprotein A (ApoA), apolipoprotein B (ApoB), apolipoprotein A/B (Apo(A/B)), fasting blood glucose (FBG), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and uric acid (UA) and serum creatinine (Cre) were measured using a Hitachi 7600 automated biochemistry analyser at the First Affiliated Hospital of Shihezi University Medical College.

RNA isolation and microRNA calculation

Whole blood samples were collected in tubes containing EDTA in the morning after 8 hs of fasting. The samples were immediately centrifuged at 3000 rpm for 10 mins at room temperature. After the separation phase, the plasma was collected, divided into two aliquots and frozen at −80 °C for later RNA isolation.

Total RNA, containing small RNA, was extracted from plasma using Trizol -Reagent (Tiangen, Biotech, Beijing, China), according to the manufacturer’s protocol. For miRNA qPCR, prior RT was performed using miRNA FastKing RT Kit (Tiangen Biotech Co, Ltd., Beijing, China, no. KR160815). For RT, 1 μg of RNA containing miRNA was polyadenylated by poly (A) polymerase and then reverse transcribed to cDNA. The cDNA (2 μl) then served as the template and was added to 1 μl primers for SYBR Green real-time PCR using miRcute Plus miRNA qPCR Detection Kit (Tiangen Biotech Co, Ltd., Beijing, China, no. FP160303). The sequence of the miR-143 specific forward primer was 5′-TGAGATGAAGCACTGTAGCTC-3′and the reverse primer was 5′-GCTGTCAACATACGCTACGTAACG-3′. The sequence of the miR-145 specific forward primer was 5′-GTCCAGTTTTCCCAGGAATCCCT-3′and the reverse primer was 5′-GCTGTCAACATACGCTACGTAACG-3′. Following the illustration in previous studies, measurements of microRNA levels were performed by quantitative RT-qPCR using cel-miR-54 as normalization control [28, 29]. The sequence of the cel-miR-54 forward primer was 5′-CCGCCCTACCCGTAATCTTCATAA-3′ and the reverse primer was 5′-GTGCAGGGTCCGAGGT-3′. The RT reaction was performed at first at 37 °C for 30 min, followed by at 42 °C for 30 min and finally at 75 °C for another 5 min. The PCR reaction was performed initially at 95 °C for 3 min, followed by repeated 40 cycles at 95 °C for 10s and latter at 60 °C for 30s. The comparative Ct method (ΔCt) was exploited to calculate the relative expression level of miR. The relative expression of each miRNA after normalization to cel-miR-54 is displayed as 2- (Ct [miRNA] -Ct[cel-miR-54]) [30].

Statistical analysis

SPSS software (SPSS, Inc., Chicago, USA) for Windows version 20.0, STATA statistics software (Version 12.0, Stata corporation, College Station, Texas 77, 845 USA) and GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA) were used for the statistical analysis. All data were subjected to a normality test (Kolmogorov-Smirnov). For the baseline characteristics of the patients and controls, the continuous variables were summarized as the means ± the SDs, and the discrete variables were summarized as counts and proportions. For the normally distributed data, one-way analysis of variance (ANOVA) and multiple comparison (LSD) tests were applied. The Kruskal-Wallis test was performed to compare the data that were not normally distributed. The significance of the microRNA level differences between the carotid artery plaque group and the no-plaque group were assessed with independent sample Student’s t-tests. The χ [2] test was used to compare the gender distributions. Pearson correlations were used to explore the relationships of the miRNAs with Hcy, the lipid parameters, and the carotid atherosclerotic plaque value. Receiver operating characteristic (ROC) curve analyses were performed to evaluate the capacities of miR-143 and miR-145 to detect Hhcy and atherosclerosis patients. Combined diagnostic accuracy of circulating miRNAs both in the all Hhcy patients and all atherosclerosis patients by using STATA statistics software. P < 0.05 was regarded as statistically significant.

Results

Significant differences in the clinical features of the four groups

The basic characteristics and clinical features of the studied groups are provided in Table 1. Hcy, TG, TC and LDL-c exhibited differences between the groups (P < 0.001). No significant differences were found in the other clinical factors, which included the gender distribution, BMI, age, HDL-c, etc. (Table 1). LSD post hoc multiple comparison tests revealed that the serum TC and LDL-c levels in the Hhcy and Hhcy + ATH groups were significantly higher than that in the NC group. Additionally, the serum TC levels in the Hhcy + ATH group were higher than those in the Hhcy and ATH groups, whereas no differences in serum LDL-c levels were found between the Hhcy + ATH, Hhcy, and ATH subjects. The TG level in the Hhcy group was higher than those in the Hhcy + ATH and NC groups (Fig. 1).
Table 1

Significant differences in clinical features among the four groups

 

NC

Hhcy

Hhcy + ATH

ATH

P-value

Males/females

10/10

14/11

20/10

15/10

0.682

Age (years)

48.00 ± 4.44

47.16 ± 5.50

49.00 ± 5.47

46.92 ± 5.20

0.445

BMI (kg/m2)

24.13 ± 2.84

23.47 ± 2.30

25.03 ± 3.58

23.13 ± 2.68

0.080

TC (mmol/l)

3.94 ± 0.79

4.60 ± 0.99

5.56 ± 1.26

4.34 ± 1.04

<0.001**

TG (mmol/l)

1.12 ± 0.07

1.37 ± 0.04

1.45 ± 0.09

1.41 ± 0.11

0.001**

HDL-c (mmol/l)

1.43 ± 0.55

1.58 ± 0.63

1.59 ± 0.57

1.82 ± 0.66

0.176

LDL-c (mmol/l)

2.74 ± 0.91

3.46 ± 0.88

3.36 ± 0.93

3.18 ± 0.81

0.043*

ApoA(g/l)

1.32 ± 0.22

1.39 ± 0.27

1.39 ± 0.41

1.47 ± 0.31

0.480

ApoA/B

1.51 ± 0.42

1.57 ± 0.5

1.42 ± 0.45

1.53 ± 0.43

0.671

ApoB(g/l)

0.96 ± 0.25

0.93 ± 0.19

1.01 ± 0.28

1.01 ± 0.31

0.580

FBG (mmol/l)

5.06 ± 0.74

4.93 ± 0.55

5.07 ± 0.5

4.93 ± 0.59

0.722

ALT (U/l)

22.8 ± 13.02

19.8 ± 10.17

27.0 ± 12.8

20.48 ± 10.86

0.100

AST (U/l)

20.25 ± 10.17

20.84 ± 10.02

20.57 ± 12.36

21.2 ± 10.73

0.993

UA (umol/l)

255.65 ± 63.2

302.96 ± 105.9

258.9 ± 114.2

224.12 ± 106.1

0.795

Cre (umol/l)

73.68 ± 22.12

75.72 ± 24.12

71.3 ± 16.16

69.88 ± 19.84

0.754

Hcy (umol/l)

9.53 ± 2.99

19.07 ± 2.85

21.90 ± 4.69

11.16 ± 2.43

< 0.001**

Continuous and categorical variables data were expressed as mean ± SEM. The statistical P value was generated by the one-way ANOVA test or Kruskal-Wallis test. χ2 test was employed to compare gender distribution. *P < 0.05 or **P < 0.001 was considered significant

Fig. 1

Multiple comparisons of baseline characteristics (Hcy, TC, TG and LDL-c) among NC, Hhcy, Hhcy + ATH and ATH subjects. Data are shown as the mean ± SD. P values were generated by one-way ANOVA test followed by the LSD post hoc multiple comparisons test. P < 0.05 or P < 0.001 was considered significant

MiR-143 and miR-145 were easily detected in the serum samples of all subjects

Before using ΔΔCt for relative gene expression, we checked the efficiency of target genes and reference gene and amplification efficiency is consistent. MiR-143 and miR-145 were stably measured in the serum samples of all subjects. No significant differences were discovered in the total RNA concentrations between the four groups (NC = 11.22 ± 2.14 ng/μl; Hhcy = 10.78 ± 1.41 ng/μl; Hhcy + ATH = 11.32 ± 1.23 ng/μl, and ATH = 11.15 ± 1.61 ng/μl) (Fig. 2a).
Fig. 2

a Concentration of all RNA samples has no significance difference among four groups. b, c The relative expression levels of miR-143 and miR-145 in the NC, Hhcy, Hhcy + ATH and ATH groups. The horizontal lines indicate the mean. P values were generated by one-way ANOVA test followed by the LSD post hoc multiple comparisons test. P < 0.05 or P < 0.001 was considered significant

As displayed in Fig. 2b and c, both miR-143 and miR-145 exhibited significant trends towards stepwise decreases from the NC (3.99 ± 1.71 and 26.47 ± 8.47, respectively) to the Hhcy (2.89 ± 1.52 and 10.67 ± 5.26, respectively) to the Hhcy + ATH (1.96 ± 1.44 and 8.31 ± 7.21, respectively) and to the ATH (1.97 ± 1.35 and 8.35 ± 6.64, respectively) groups. No significant difference was found between the Hhcy and Hhcy + ATH subjects.

Expression levels of miR-143/145 in the carotid plaque group versus the no plaque group

To better understand the pathophysiology of the atherosclerotic process, we compared the expressions of the candidate miRNAs in the atherosclerotic plaque and normal arteries. Among all subjects, 55 patients had carotid artery plaques (35 men and 20 women; mean age = 48.15 ± 5.36 years), and 45 patients had no plaques (24 men and 21 women, mean age = 47.53 ± 5.02 years). Lower levels of the expressions of miR-143 and miR-145 (1.97 ± 1.39 vs 3.38 ± 1.69 and 8.33 ± 6.90 vs 17.69 ± 10.45; P < 0.001) were observed in the carotid artery plaque group compared with the no-plaque group (Fig. 3).
Fig. 3

MiR-143 and miR-145 levels in carotid plaques group and non-plaque group. P < 0.001 was considered significant. Carotid plaques, all objects with carotid plaque (Hhcy + ATH and ATH group); Non-plaque, all objects without carotid plaque (NC and Hhcy group)

Correlations of miR-143 and miR 145 with Hcy and the lipid parameters

Baseline data about the correlations of miR-143/miR-145 with Hcy and the lipid parameters are presented in Table 2 and the Additional files (Additional file 1: Figure S1, Additional file 2: Figure S2, and Additional file 3: Figure S3). Pearson’s correlation analyses demonstrated that Hcy was positively correlated with TC (r = 0.299, P = 0.003) and LDL-c (r = 0.279, P = 0.005). The miR-143 expression level exhibited negative correlations with Hcy (r = −0.214, P = 0.032), TC (r = −0.390, P < 0.001) and LDL-c (r = −0.608, P < 0.001). The miR-145 expression level also exhibited negative correlations with Hcy (r = −0.347, P < 0.001), TC (r = −0.468, P < 0.001), TG (r = −0.594, P < 0.001) and LDL-c (r = −0.219, P = 0.028). However, no correlation was found between miR-143 and TG. Similarly, no correlation of miR-143/miR-145 with ApoA, ApoB, ApoA/B, age, BMI and no association of miR-143/miR-145 with gender, were found (P > 0.05).
Table 2

Correlations between miRNAs and Hcy, lipid profiles in all groups

  

TC

LDL-c

TG

miR-143

miR-145

Hcy

r

0.299

0.279

0.053

−0.214

−0.347

P

0.003*

0.005*

0.604

0.032*

<0.001**

TC

r

 

0.337

0.080

−0.390

−0.468

P

 

0.001*

0.429

<0.001**

<0.001**

LDL-c

r

  

0.066

−0.608

−0.594

P

  

0.513

<0.001**

<0.001**

TG

r

   

−0.123

−0.219

P

   

0.223

0.028*

miR-143

r

    

0.690

P

    

<0.001**

Pearson’s correlation correlations were presented as correlation coefficients (r) and significance (P), *P < 0.05 or **P < 0.001 was considered significant

ROC curves for miR-143/145 for the definite detection of Hhcy and ATH patients

To further evaluate the predictive power of atherosclerosis-associated miR-143 and miR-145 for Hhcy. All those subjects were divided into hyperhomocysteinaemia patient (34 men and 21 women; mean age 48.16 ± 5.51 years) and atherosclerosis patient (35 men and 20 women; mean age 48.15 ± 5.36 years) groups, and ROCcurves were constructed to estimate the sensitivities and specificities of miR-143/miR-145 levels for the detection of Hhcy and ATH patients. As shown in Fig. 4a and b, ROC curve analysis of miR-143 or miR-145 exhibited strong differentiation power between Hhcy patients and other groups (NC and ATH). The AUC of miR-143 or miR-145 in Hhcy patients was 0.775 (P < 0.001), 0.681 (P < 0.001). Interestingly, the combination of the two miRNAs resulted in a little lower AUC value of 0.773 (P < 0.001) than the AUC of miR-143 or miR-145 (Fig. 2a–c). These data suggested that the combination of circulating miR-143 and miR-145, which were equal to the sensitivity and specificity of miR-143 alone for diagnosing Hhcy. In contrast, the miR-143 and miR-145 levels did not significantly aid the detection of between ATH patients and other groups (NC and Hhcy) (Fig. 5ac).
Fig. 4

ROC curve for plasma (a) miR-143, (b) miR-145, and (c) the combination of the two miRNAs were able to distinguish all Hhcy patients (Hhcy + ATH and Hhcy) from the (NC and ATH) cases

Fig. 5

ROC curve for plasma (a) miR-143, (b) miR-145, and (c) the combination of the two miRNAs were able to distinguish all atherosclerosis patients (Hhcy + ATH and ATH) from the (NC and Hhcy) cases

Discussion

The present study is the only study to demonstrate the link between atherosclerosis-associated miR-143 and miR145 and hyperhomocysteinaemia in humans. In this study, all the subjects involved were freshly diagnosed with Hhcy and had never undergone any intervention whatsoever. Our study identified miR-143 and miR-145 as potential non-invasive biomarkers for Hhcy, which may be helpful in predicting the progress of atherosclerosis in Hhcy patients.

In this study, Hcy was positively correlated with TC and LDL-c, which indicates that elevated serum homocysteine might be closely related to dyslipidaemia and aggravate atherosclerosis. Meanwhile, qRT-PCR results showed that plasma miR-143 and miR-145 were visibly down-regulated in Hhcy + ATH patients. Pearson’s correlations revealed that the miR-143/−145 expression levels were negatively correlated with Hcy, TC, LDL-c or TG. The ROC analyses showed that the miR-143 might be suitable diagnostic markers for the detection of all Hhcy patients, including Hhcy and Hhcy + ATH patients.

Several studies have demonstrated that miR-143/−145 are molecular keys that determine VSMC phenotypic switching and are essential for VSMC differentiation [12], which is known to contribute to atherogenesis [3133]. We found that that high level of LDL-c and Hcy are most important risk factor for atherosclerosis. And our data shows that miR-143/−145 expression level was negatively correlated with Hcy and LDL-c. Our data support the notion that Hcy was positively correlated with LDL-c. Several studies have demonstrated that elevated Hcy makes the correlation with LDL-c [34, 35]. This study demonstrated that elevated homocysteine levels may increase the risk of atherosclerosis.

The role of homocysteine in vascular plaque formation is multifactorial and includes smooth muscle proliferation, endothelial dysfunction and inflammation [36]. Previous studies have also confirmed the connection between Hhcy and dyslipidaemia, which is consistent with the results of present study [37]. The down-regulations of miR-145 and miR-143 in injured or atherosclerotic vessels are associated with proliferating, less differentiated smooth muscle cells [38]. Interestingly, miR-143/−145 are significantly down-regulated in clinical atherosclerotic plaque arteries compared with healthy arteries, which suggests that increasing miR-143 and miR-145 levels might contribute to the prevention of atherosclerotic plaque formation.

Because miR-143 and miR-145 are expressed in VSMCs, endothelial cells and inflammatory cells, it is not surprising that several animal and clinical studies have already demonstrated that miR-143 and miR-145 contribute to the pathogenesis of atherosclerosis [33, 39, 40]. MiR-145 has been found to be down-regulated in the proliferative VSMCs of atherosclerotic arteries in ApoE-knockout mice [41]. This finding implies that the down-regulation of miR-145 may contribute to atherogenesis. Hai Gao et al. [41] demonstrated that the plasma level of miR-145 is significantly lower in CAD patients compared to healthysubjects. This finding reveals that circulating miR-145 has been demonstrated to be regulated during coronary atherosclerosis. These studies indicate that miR-145 is involved in vascular injury and the migratory activity of VSMCs. In our study, the expressions of miR-143 and miR-145 were found to be down-regulated in individuals with carotid artery plaques. The athero-protective roles of miR-143 and miR-145 may be attributed to their abilities to promote the contractile VSMC phenotype and inhibit the synthetic VSMC phenotype, the latter of which is associated with atherosclerosis [6, 14].

MiRNA-based therapy has been regarded as a promising method for clinical applications in the treatment of cardiovascular diseases [42, 43]. Targeting miR-143/−145 may be a promising therapy for these cardiovascular diseases. However, to date, no miRNAbased therapy has been developed to treat cardiovascular diseases in human clinical trials. Several animal studies have demonstrated that targeting miR-143/−145 may be a promising therapy for vascular diseases. Our data just indicate that miR-143/−145 may be potential non-invasive markers of atherosclerosis in Hhcy patients, and our results may be impetus for these circulating miRNAs as prognostic biomarkers before long and possibly as therapeutic targets of atheroscleorsis in Hhcy patients.

Remarkably, the plasma microRNA levels were not affected by a wide range of clinical confounders, including age, sex, body mass index, kidney function, hepatic function and fasting blood glucose level.

The current study not only corroborated previous animal studies of the effect of hyperhomocysteinaemia on atherosclerosis but also linked atherosclerosis-associated microRNAs and hyperhomocysteinaemia in humans. This relationship provides novel insight into the pathophysiology of atherosclerosis. Ourstudy has some limitations. First, the mechanisms of miR-143/−145 in regulating atherosclerosis are still not entirely clear in Hhcy human and unexplored in this study, while the underlying mechanisms postulated were based on previous studies. Further experimental studies are needed to explore unknown functions of miR-143/−145 that was expressed in Hhcy patients. Carotid intima-media thickness (CIMT) could not be applied as an evaluation index for atherosclerosis due to a lack of equipment in the hospital. Another potential limitation of our study is the small number of patients available due to the low prevalence of hyperhomocysteinaemia.

Conclusion

In conclusion, we demonstrated that atherosclerosis-related circulating miR-143/miR-145 have significantly variable expressions between NC, Hhcy, Hhcy + ATH and ATH individuals and between carotid plaque and no-plaque individuals. This study revealed that the miR-143/−145 expression levels were positively associated with Hcy and lipidaemia. Moreover, this study indicated that miR143may be regarded as a potential non-invasive biomarkers of atherosclerosis in patients with hyperhomocysteinaemia. However, prospective large-scale studies are required to determine the potential value of circulating miRNAs for the determination of atherosclerosis in patients with hyperhomocysteinaemia.

Abbreviations

ALT: 

Alanine aminotransferase

ApoA: 

Apolipoprotein A; Apo A/B, apolipoprotein A/B

ApoB: 

Apolipoprotein B

AST: 

Aspartate aminotransferase

ATH: 

Carotid artery atherosclerosis alone subjects

BMI: 

Body mass index

Cre: 

Serum creatinine

FBG: 

Fasting blood glucose

Hcy: 

Homocysteine

HDL-c: 

High-density lipoprotein cholesterol

Hhcy: 

Hyperhomocysteinaemia alone subjects

Hhcy + ATH: 

Hyperhomocysteinaemia and carotid artery atherosclerosis combined subjects

LDL-c: 

Low-density lipoprotein cholesterol

NC: 

Normal control subjects

TC: 

Total cholesterol

TG: 

Triglyceride

UA: 

Uric acid

Declarations

Acknowledgements

We thank Inayat Azeem from Pakistan for assistance in language review.

Availability of data and material

Data cannot be shared publicly. Datasets are available from the corresponding author by request.

Funding

This work was supported by National Natural Science Foundation of China (Grant nos. 81,270,353, 81,160,001).

Authors’ contributions

KJ L, SX and JD W performed the data analysis and drafted the manuscript. JD W, KJ L and SX designed the study. KJ L, YY and YZ made the graphics. YL, RC, YP and XW L collected the clinical data, and the collection was supervised by JD W and. KJ L, YP, XW L, YY and YZ performed the laboratory experiments, which were supervised and analysed by JD W and XM G. All authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not Applicable.

Ethics approval and consent to participate

The entire study was approved by the ethical committee of the First Affiliated Hospital of Shihezi University Medical College. All requirements of the Declaration of Helsinki were met. The patients were fully informed of the study procedures before they provided consent.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
(2)
Department of Cardiology, the First Affiliated Hospital, Shihezi University School of Medicine
(3)
The Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University

References

  1. Li F, Chen Q, Song X, Zhou L, Zhang J. MiR-30b is involved in the Homocysteine-induced apoptosis in human coronary artery endothelial cells by regulating the expression of Caspase 3. Int J Mol Sci. 2015;16(8):17682–95.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Schaffer A, et al. Relationship between homocysteine and coronary artery disease. Results from a large prospective cohort study. Thromb Res. 2014;134(2):288–93.View ArticlePubMedGoogle Scholar
  3. Alpert MA. Homocyst(e)ine, atherosclerosis, and thrombosis. South Med J. 1999;92(9):858–65.View ArticlePubMedGoogle Scholar
  4. Jeon SB, Kang DW, Kim JS, Kwon SU. Homocysteine, small-vessel disease, and atherosclerosis: an MRI study of 825 stroke patients. Neurol. 2014;83(8):695–701.View ArticleGoogle Scholar
  5. Meng L, et al. Polyphenols and polypeptides in Chinese Rice wine inhibit Homocysteine-induced proliferation and migration of vascular smooth muscle cells. J Cardiovasc Pharmacol. 2016;67(6):482–90.View ArticlePubMedGoogle Scholar
  6. Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta medica Indonesiana. 2007;39(2):86–93.PubMedGoogle Scholar
  7. Dubland JA, Francis GA. So much cholesterol: the unrecognized importance of smooth muscle cells in atherosclerotic foam cell formation. Curr Opin Lipidol. 2016;27(2):155–61.View ArticlePubMedGoogle Scholar
  8. Deddens JC, et al. Circulating MicroRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome. J Cardiovasc Transl Res. 2013;6(6):884–98.View ArticlePubMedGoogle Scholar
  9. Gao Y, et al. Functional regulatory roles of microRNAs in atherosclerosis. Clin Chim Acta. 2016;460:164–71.View ArticlePubMedGoogle Scholar
  10. Maegdefessel L. The emerging role of microRNAs in cardiovascular disease. J Intern Med. 2014;276(6):633–44.View ArticlePubMedGoogle Scholar
  11. Duan H, et al. MicroRNA-217 suppresses homocysteine-induced proliferation and migration of vascular smooth muscle cells via N-methyl-D-aspartic acid receptor inhibition. Clin Exp Pharmacol Physiol. 2016;43(10):967–75.View ArticlePubMedGoogle Scholar
  12. Cordes K, Sheehy R. N.T, white M.P. et al. MiR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nat. 2009;460(7256):705–10.Google Scholar
  13. Zhang HP, et al. A regulatory circuit involving miR-143 and DNMT3a mediates vascular smooth muscle cell proliferation induced by homocysteine. Mol Med Rep. 2016;13(1):483–90.PubMedGoogle Scholar
  14. Boettger T, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Investig. 2009;119(9):2634–47.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Guo X, et al. MiRNA-145 inhibits VSMC proliferation by targeting CD40. Sci Rep. 2016;6:35302.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Shimizu C, et al. Differential expression of miR-145 in children with Kawasaki disease. PLoS One. 2013;8(3):1–12.View ArticleGoogle Scholar
  17. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008;79(4):581–8.View ArticlePubMedGoogle Scholar
  18. Baldan A, Fernandez-Hernando C. Truths and controversies concerning the role of miRNAs in atherosclerosis and lipid metabolism. Curr Opin Lipidol. 2016;27(6):623–9.View ArticlePubMedGoogle Scholar
  19. Kontaraki JE, Marketou ME, Zacharis EA, et al. Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension. J Hum Hypertens. 2014;28(8):510–6.View ArticlePubMedGoogle Scholar
  20. Fu X, Guo L, Jiang ZM, et al. An miR-143 promoter variant associated with essential hypertension. Int J Clin Exp Med. 2014;7(7):1813–7.PubMedPubMed CentralGoogle Scholar
  21. Hu B, Song JT, Qu HY, et al. Mechanical stretch suppresses microRNA-145 expression by activating extracellular signalregulated kinase 1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype. PLoS One. 2014;9(5):e96338.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Turczynska KM, Sadegh MK, Hellstrand P, et al. MicroRNAs are essential for stretch-induced vascular smooth muscle contractile differentiation via microRNA (miR)-145-dependent expression of L-type calcium channels. J Biol Chem. 2012;287(23):19199–206.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nat. 2011;473:317–25.View ArticleGoogle Scholar
  24. Xin M, Small EM, Sutherland LB, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23:2166–78.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Cheng Y, Liu X, Yang J, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009;105:158–66.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Kesherwani V, Nandi SS, Sharawat SK, Shahshahan HR, Mishra PK. Hydrogen sulfide mitigates homocysteine-mediated pathological remodeling by inducing miR-133a in cardiomyocytes. Mol Cell Biochem. 2015;404(1–2):241–50.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Arslan A, et al. The relationship between serum paraoxonase levels and carotid atherosclerotic plaque formation in Alzheimer's patients. Neurol Neurochir Pol. 2016;50(6):403–9.PubMedGoogle Scholar
  28. Kuhlmann JD, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer. Clin Chem. 2014;60(1):206–13.View ArticlePubMedGoogle Scholar
  29. Baraniskin A, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer. 2013;132(2):E48–57.View ArticlePubMedGoogle Scholar
  30. Wang GK, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659–66.View ArticlePubMedGoogle Scholar
  31. Lovren F, et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circ. 2012;126(11):S81–90.View ArticleGoogle Scholar
  32. Sala F, et al. MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr−/−mice. Thromb Haemost. 2014;112(4):796–802.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L. MiR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circ Cardiovasc Genet. 2014;4(2):197–205.View ArticleGoogle Scholar
  34. Seo H, Oh H, Park H, et al. Contribution of dietary intakes of antioxidants to homocysteine-induced low density lipoprotein (LDL) oxidation in atherosclerotic patients. Yonsei Med J. 2010;51(4):526–33.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Chernyavskiy I, Veeranki S, Sen U, Tyagi SC. Atherogenesis: hyperhomocysteinemia interactions with LDL, macrophage function, paraoxonase 1, and exercise. Ann N Y Acad Sci. 2016;1363(1):138–54.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Pang H, Han B, Fu Q, Zong Z. Association of High Homocysteine Levels with the risk stratification in hypertensive patients at risk of stroke. Clin Ther. 2016;38(5):1184–92.View ArticlePubMedGoogle Scholar
  38. Navickas R, et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res. 2016;111(4):322–37.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Santovito D, et al. Overexpression of microRNA-145 in atherosclerotic plaques from hypertensive patients. Expert Opin Ther Targets. 2013;17(3):217–23.View ArticlePubMedGoogle Scholar
  40. Liu X, et al. Flank sequences of miR-145/143 and their aberrant expression in vascular disease: mechanism and therapeutic application. J Am Heart Assoc. 2013;2(6):e000407.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Gao H, et al. Plasma levels of microRNA-145 are associated with severity of coronary artery disease. PLoS One. 2015;10(5):e0123477.View ArticlePubMedPubMed CentralGoogle Scholar
  42. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012;11(11):860–72.View ArticlePubMedGoogle Scholar
  43. Dangwal S, Tum T. MicroRNA therapeutics in cardiovascular disease models. Annu Rev Pharmacol Toxicol. 2014;54:185–203.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement